Skip to main content
GutCited

Bifidobacterium breve pour Irritable Bowel Syndrome (IBS)

D

Limited data from small studies. Preliminary evidence for symptom improvement.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dbreve\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

D

En conclusion

Limited data from small studies. Preliminary evidence for symptom improvement.

Key Study Findings

Review
Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases.
Dose: None vs: None Outcome: None Effet: None None

Population: None

Other n=1098 8 weeks Open-label
A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of …
Dose: None vs: None (single-arm open-label) Outcome: Treatment success for abdominal pain and bloating Effet: 73% pain, 81.9% bloating success at T1 <0.001

Population: IBS patients from 52 Italian gastroenterologists

Randomized Controlled Trial n=61 8 weeks Double-blind
Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with …
Dose: None vs: Placebo Outcome: IBS-SSS symptom severity score change Effet: None None

Population: Patients with moderate-severe diarrhea-predominant IBS

Randomized Controlled Trial 4 weeks
Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …
Dose: 2 g vs: Placebo Outcome: Constipation symptoms Effet: None P = 0.005

Population: IBS patients

Review
Postbiotics: A new member in the biotics family.
Dose: None vs: None Outcome: Clinical applications overview Effet: None None

Population: General population (review)

In Vitro
Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal …
Dose: None vs: None Outcome: Colitis severity Effet: None None

Population: Crohn's disease patients

Key Statistics

2

Études

150

Participants

Positive

D

Note

Referenced Papers

Archivos argentinos de … 2024 3 citations
Journal of clinical … 2004 205 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
1-10 billion CFU/day
adultgisupport:
5-10 billion CFU/day
neonatalsupport:
1-5 billion CFU/day (as directed by pediatrician)

Limite supérieure : Well-tolerated up to 10 billion CFU/day in clinical trials

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Mixed --
None 8 weeks Positive 1098
None 8 weeks Neutral 61
2 g 4 weeks Mixed --
None -- Positive --
None -- Positive --
Serum-derived bovine immunoglobulin (SBI) -- Positive --
None -- Positive --

Moment optimal de prise : Before meals or on empty stomach; for infants, mix with breast milk or formula

Safety & Side Effects

Effets indésirables signalés

  • Mild gas during initial use
  • Occasional loose stools in infants (transient)
  • Rare abdominal discomfort
  • Very rare: bacteremia in immunocompromised individuals

Interactions connues

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (use with caution in immunocompromised patients)

Apport maximal tolérable : Well-tolerated up to 10 billion CFU/day in clinical trials

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium breve?
Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.

Related Evidence

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.